RFL vs CRIS vs IMVT vs MGNX

For growth investors, Rafael Holdings, Inc.

(RFL) is the stronger pick with 44. 0% revenue growth year-over-year, versus -13. 4% for Curis, Inc. (CRIS). Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -99. 7% for Curis, Inc. (CRIS). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus CRIS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Rafael Holdings, Inc.

(RFL) is the lower-risk stock at 0. 99β versus Curis, Inc. 's 1. 92β — meaning CRIS is approximately 93% more volatile than RFL relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 66% for MacroGenics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Rafael Holdings, Inc.

(RFL) is pulling ahead at 44. 0% versus -13. 4% for Curis, Inc. (CRIS). On earnings-per-share growth, the picture is similar: Curis, Inc. grew EPS 91. 6% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, RFL leads at 30. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immunovant, Inc.

(IMVT) is the more profitable company, earning 0. 0% net margin versus -33. 3% for Rafael Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -28. 5% for RFL. At the gross margin level — before operating expenses — CRIS leads at 99. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Rafael Holdings, Inc.

(RFL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99)). Curis, Inc. (CRIS) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RFL: -73. 5%, CRIS: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RFL (Real Estate) and CRIS (Healthcare) and IMVT (Healthcare) and MGNX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RFL is a small-cap high-growth stock; CRIS is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; MGNX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.